Neuropharmaceuticals, Neurodevices, Neurodiagnostics
• Psychiatry
21st century psychiatry will change as the data gathered by the Human Genome Project enhances our understanding of the biochemistry of mental illness:
According to NeuroInsights, Neurological diseases and psychiatric illnesses represent the largest and fastest growing unmet medical market: 1.5 billion people worldwide. Building on decades of brain research and the success of the Human Genome Project, neurotechnology companies hold the greatest potential for major scientific discoveries, commercial success and sustainable investment opportunities.
The neurotechnology industry includes companies researching, developing and marketing pharmaceuticals, biologics, medical devices, as well as diagnostic and surgical equipment for the treatment of neurological and psychiatric illnesses.
NeuroInsights has identified three sectors within the $110 billion industry:
neuropharmaceuticals, neurodevices and neurodiagnostics.
Neurotechnology companies face fundamentally different investment requirements, research and development challenges, regulatory milestones and social drivers that sets them apart from other life science and health care companies.